Papers › leukemia › 4342187

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial

The Lancet. Oncology · 01-2-2015 · 4342187 on PMC →

366 citations FWCI 29.53 Chronic Lymphocytic Leukemia Research Trend

Citation data as of 2026-04-12 (OpenAlex).

Extracted findings

This paper hasn't been extracted into the knowledge graph yet. We're working through the corpus — 4342187 is in the queue.

In the meantime: Browse leukemia papers → · Ask about this topic → · Explore the graph →